QPS Neuropharmacology is experienced in generating, characterizing and maintaining of transgenic disease models and using them for drug testing projects for more than 15 years.
The mouse and rat models available for drug development in Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Huntington’s Disease (HD), Niemann-Pick Disease, Gaucher Disease, Amyotrophic Lateral Sclerosis (ALS) , Autism Spectrum Disorder (ASD), Schizophrenia, Frontotemporal Lobar Degeneration (FTLD), and other neurodegenerative diseases allow the quantitative evaluation of compound interactions with amyloid, tau, inflammation related markers, mitochondrial deficiency and other pathologies.
We are happy to receive any inquiry to elaborate the most efficient way, including behavioral, immunohistochemical, biochemical and molecular biological techniques, for the support of your drug development approach.
Our biobank can provide samples (brain tissue, CSF, etc.) of our animal models for analyses in your laboratory.
Amyotrophic Lateral Sclerosis
Frontotemporal Lobar Degeneration
Lysosomal Storage Diseases: